BioCentury
ARTICLE | Clinical News

Pariet rabeprazole regulatory update

February 17, 2014 8:00 AM UTC

Eisai disclosed in its earnings for the third quarter of the fiscal year ending March 31, 2014, that it submitted in November a regulatory application in Japan to expand the label of Pariet rabeprazole to include the prevention of recurrence of gastric and duodenal ulcers during treatment with low-dose aspirin. The company also said it submitted an application for a 5 mg dose formulation of the proton pump inhibitor (PPI). A 20 mg formulation of Pariet is already approved in Japan to treat gastric and duodenal ulcers and reflux esophagitis and to eradicate Helicobacter pylori infections. ...